Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

The Chronic Kidney Disease Therapeutics Market is Forecast to Show Moderate Growth Until 2016

Online PR News – 09-March-2010 – – GlobalData’s analysis suggests that the global chronic kidney disease (CKD) market was worth $13.3 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.9% for the next seven years to reach $19.8 billion by 2016. The market is expected to be driven by an increase in prevalence and the treatment seeking population and in part is due to the introduction of Feraheme to treat anemia related to CKD. The global market revenues are expected to increase due to the introduction of new therapies which are currently in the regulatory filing stage and those in the later stages of development. These drugs include antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and efficacy, nutritional supplements and iron replacement therapies.

For further details, please click or add the below link to your browser:

GlobalData analyzed the current competitive landscape for CKD drugs and found the competition to be weak. There are more than 12 marketed products for the treatment of CKD, including angiotensin II receptor blockers, Angiotensin Converting Enzyme (ACE) inhibitors, phosphate binders, Erythropoietin (EPO) and iron replacement products. Although these products are moderately effective in controlling the progression of CKD, the serious adverse effects of these products has resulted in the discontinuation of therapies amongst patients. The market is in need of a first-in-class product which is efficient in slowing down the progression of CKD.

GlobalData has found that the global CKD market is highly lucrative, where there is a substantial amount unmet need to be satisfied with respect to the safety of medications. Serious adverse events associated with lanthanum carbonate, sevelamer carbonate, sevelamer hydrochloride and other phosphate binders create a need for products with better safety profiles and higher efficacy. In addition, the dosing regimen of the products is highly prohibitive for patients to remain on long-term treatment. As a result of discontinuation, only half of the patients meet the hyperphosphatemia treatment guidelines required for slowing down the disease progression.

For further details, please click or add the below link to your browser:

GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store: